From the Annual Report:
"Invion has completed most of the preclinical studies required before the start of clinical trials. There are a few bodies of work
that are currently in progress, such as dose range finding and formulation optimisation and bioavailability, that are expected
to be completed in the coming months."
Will be unlikely this year according to the above.
GLTA
From the Annual Report:"Invion has completed most of the...
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $13.53M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $37.23K | 13.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 48653340 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 5000000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| IVX (ASX) Chart |